Search Results

You are looking at 1-10 of 51

Severe Intraoperative Bronchospasm Treated with a Vibrating-Mesh Nebulizer
Leonard R. GoldenMD,
Helen Ann DeSimoneDDS,
Farhad YeroshalmiDMD,
Mindaugas PraneviciusMD, and
Mana SaraghiDMD
Article Category: Other
Volume/Issue: Volume 59: Issue 3
Online Publication Date: Jan 01, 2012
DOI: 10.2344/12-00003.1
Page Range: 123 – 126

Asthma is an episodic disease characterized by hyperreactive bronchi, chronic airway inflammation, and airflow obstruction during expiration. Bronchospasm is caused by spasmodic contraction of the bronchial smooth muscle. Status asthmaticus is bronchospasm that does not respond to standard treatments, which include intravenous (IV), inhaled, and subcutaneous (SQ) interventions. It is estimated that 9.6 million children in the USA have been diagnosed with asthma. This represents approximately 13% of the total pediatric population. 1 , 2 The

Download PDF
; Assembly of conventional anesthesia circuit with APN and size-specific connectors. A indicates the universal adapter (Intersurgical Incorporated, #1969, Liverpool, NY) with a 22-mm outer diameter (OD) and a 15-mm inner diameter (ID); B, the APN chamber; C, the straight connector (Intersurgical Incorporated, #1962, Liverpool, NY) with a 15-mm OD and 22-mm ID; and D, the APN control module, which connects to the APN chamber via a cable.
Leonard R. Golden,
Helen Ann DeSimone,
Farhad Yeroshalmi,
Mindaugas Pranevicius, and
Mana Saraghi

Assembly of conventional anesthesia circuit with APN and size-specific connectors. A indicates the universal adapter (Intersurgical Incorporated, #1969, Liverpool, NY) with a 22-mm outer diameter (OD) and a 15-mm inner diameter (ID); B, the APN chamber; C, the straight connector (Intersurgical Incorporated, #1962, Liverpool, NY) with a 15-mm OD and 22-mm ID; and D, the APN control module, which connects to the APN chamber via a cable.


Figure 1; Synthesis and function of prostanoids. Perturbation of cell membranes can be mediated by diverse endogenous and exogenous stimuli. This triggers activity of phospholipase A2, releasing arachidonic acid from the phospholipids making up the membrane. Two families of cyclooxygenases (COX-1 and COX-2) convert this fatty acid to a variety of so-called prostanoids that are unique to the particular cell or tissue and include prostaglandins, thromboxanes, and prostacyclin. Each of these prostanoids has specific physiological functions, some of which are listed in the table within this figure. Most nonsteroidal anti-inflammatory drugs (NSAIDs) are nonselective and inhibit both COX-1 and COX-2 families. Celecoxib (Celebrex) is representative of agents that selectively inhibit COX-2; it reduces pain and inflammation with little or no influence on gastric mucosa. However, this selective inhibition may promote greater synthesis of prostanoids derived from COX-1, including thromboxane-mediated effects leading to possible thrombotic events (eg, myocardial infarction, stroke). Arachidonic acid is also a substrate for lipoxygenase that catalyzes the formation of leukotrienes known for their anaphylactoid effects, including bronchospasm and upper airway edema. As NSAIDs inhibit the activity of cyclooxygenases, a greater portion of arachidonic acid can be converted to leukotrienes by lipoxygenase. This may not be tolerated by patients with atopy because they experience pseudoallergic syndromes.
Daniel E. Becker
Figure 1
Figure 1

Synthesis and function of prostanoids. Perturbation of cell membranes can be mediated by diverse endogenous and exogenous stimuli. This triggers activity of phospholipase A2, releasing arachidonic acid from the phospholipids making up the membrane. Two families of cyclooxygenases (COX-1 and COX-2) convert this fatty acid to a variety of so-called prostanoids that are unique to the particular cell or tissue and include prostaglandins, thromboxanes, and prostacyclin. Each of these prostanoids has specific physiological functions, some of which are listed in the table within this figure. Most nonsteroidal anti-inflammatory drugs (NSAIDs) are nonselective and inhibit both COX-1 and COX-2 families. Celecoxib (Celebrex) is representative of agents that selectively inhibit COX-2; it reduces pain and inflammation with little or no influence on gastric mucosa. However, this selective inhibition may promote greater synthesis of prostanoids derived from COX-1, including thromboxane-mediated effects leading to possible thrombotic events (eg, myocardial infarction, stroke). Arachidonic acid is also a substrate for lipoxygenase that catalyzes the formation of leukotrienes known for their anaphylactoid effects, including bronchospasm and upper airway edema. As NSAIDs inhibit the activity of cyclooxygenases, a greater portion of arachidonic acid can be converted to leukotrienes by lipoxygenase. This may not be tolerated by patients with atopy because they experience pseudoallergic syndromes.


Elliot HaybargerDMD,
Andrew S. YoungDDS, and
Joseph A. Giovannitti JrDMD
Article Category: Research Article
Volume/Issue: Volume 63: Issue 3
Online Publication Date: Jan 01, 2016
Page Range: 160 – 167

. Unfortunately, follow-up allergy tests did not reveal clear evidence of allergic drug reaction. The surgery was postponed and completed without incident a week later under general anesthesia with sevoflurane. Further discussion on benzodiazepine allergy will follow a basic concepts review for anaphylaxis including clinical features, diagnosis, allergy testing, and management. ANAPHYLAXIS Anaphylaxis is a life-threatening condition marked by cardiovascular collapse, generalized interstitial edema, and bronchospasm. It may occur through

Cara J. RileyDMD, MS,
Timothy MooreCRNA, MS, MSNA,
Lauren Eagelston,
Dale BurkettMD,
Scott AuerbachMD, and
Richard J. IngMBBCh, FCA(SA)
Article Category: Case Report
Volume/Issue: Volume 64: Issue 1
Online Publication Date: Jan 01, 2017
Page Range: 29 – 32

patient later showed signs of bronchospasm with oxygen saturations ranging from the low 80s% to mid 90s%, and the anesthetic was terminated after the most urgent dental needs were addressed. Two other anesthetic records noted laryngospasm and coughing, easily treated, with uneventful courses thereafter. For this anesthetic, we secured a 22-gauge peripheral intravenous (IV) catheter in the preoperative area. The patient received 2 mg IV midazolam for anxiolysis and was transported to the operating room. Induction of anesthesia was carefully titrated with a total

S. ThikkurissyDDS, MS,
Bethany CrawfordDDS,
Judith GronerMD,
Roderick StewartEMT-B, and
Megann K. SmileyDDS, MS
Article Category: Other
Volume/Issue: Volume 59: Issue 4
Online Publication Date: Jan 01, 2012
Page Range: 143 – 146

, laryngospasm, bronchospasm, airway obstruction, hypersecretion, and coughing. For each type of adverse event experienced by the child, the anesthesiologist also rated the severity of the event on scale of 0 to 3, 0 being the absence of an event, 3 being the most severe manifestation of that event. At the conclusion of the procedure, the patient was carefully suctioned and extubated deep in the GA suite. The patient was allowed to recover until he or she met criteria for phase I recovery. The patient was then transported to an adjacent phase II recovery unit where he or she

Kazumasa KubotaDDS, PhD,
Tomoyuki MiyamotoDDS,
Takutoshi InoueDDS, and
Haruhisa FukayamaDDS, PhD
Article Category: Research Article
Volume/Issue: Volume 65: Issue 2
Online Publication Date: Jan 01, 2018
Page Range: 106 – 110

hydrochloride-felypressin, for local anesthesia, were administered during the operation. Anesthesia maintenance was uneventful with 1.5 to 2.5% sevoflurane and 33% air/oxygen. Return of neuromuscular function was confirmed, and the tracheal tube was successfully removed and did not induce bronchospasm. The patient was brought back to the ward thereafter. Control of postoperative pain ( Figures 1 and 3 ): IOP was applied 90 minutes after the patient returned to the ward for a reported VAS of 30. Application of IOP with 4% lidocaine for 30 minutes reduced the VAS to 0

Robert L. CampbellDDS,
Navin S. ShettyDDS,
Kaavya S. Shetty,
Herbert L. PopeDDS, and
Jeffrey R. CampbellDDS
Article Category: Research Article
Volume/Issue: Volume 65: Issue 4
Online Publication Date: Jan 01, 2018
Page Range: 225 – 230
Article Category: Other
Volume/Issue: Volume 59: Issue 4
Online Publication Date: Dec 01, 2012
Page Range: 172 – 172

Adrenergic agonists, 159 Adrenergic antagonists, 159 Amnesia, 62 Anesthesia, 82 Anesthetics local, 57 Anticholinergic drugs, 159 Asthma, 123 Autonomic drugs, 159 Biocompatibility testing, 57 Bronchospasm, 123 Buffering, 127 Cholinergic drugs, 159 Complication, 82 Cost analysis, 147 Deep sedation, 107 Demand for services, 3 Dental anesthesia, 147 Dental anesthesiologist, 3 Dental caries, 143

Steven GanzbergDMD, MS
Article Category: Editorial
Volume/Issue: Volume 63: Issue 1
Online Publication Date: Jan 01, 2016
Page Range: 1 – 2

one of the most critical to use for any dental sedation/anesthesia provider. We know that the majority of adverse sedation/GA events that occur in dental practice involve airway concerns. Anatomic upper airway obstruction, laryngospasm, and foreign body obstruction probably lead the list. Bronchospasm and aspiration round out the major common diagnoses, although the differential for adverse airway/pulmonary emergencies is vast. When seconds matter in the management of an airway emergency, having everything needed immediately at hand is very beneficial. Are